Immunome (IMNM) Common Equity (2019 - 2026)

Immunome (IMNM) has 8 years of Common Equity data on file, last reported at $588.7 million in Q1 2026.

• Quarterly Common Equity rose 91.68% year-over-year to $588.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $588.7 million (up 91.68% YoY) and the FY2025 annual result came in at $634.3 million, up 250.15% from the prior year.
• Common Equity eased to $588.7 million in Q1 2026, from $634.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $634.3 million in Q4 2025 to a low of $6.1 million in Q3 2023.
• A 5-year average of $191.5 million and a median of $181.2 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity plunged 73.68% — and 2024, when it surged 3436.97%.
• Tracing IMNM's Common Equity over 5 years: stood at $16.7 million in 2022, then soared by 619.88% to $119.9 million in 2023, then jumped by 51.12% to $181.2 million in 2024, then surged by 250.15% to $634.3 million in 2025, then decreased by 7.2% to $588.7 million in 2026.
• The last three Common Equity figures came in at $588.7 million (Q1 2026), $634.3 million (Q4 2025), and $263.9 million (Q3 2025), per Business Quant data.